Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 1
1991 14
1992 15
1993 10
1994 18
1995 31
1996 19
1997 32
1998 25
1999 27
2000 33
2001 25
2002 19
2003 22
2004 21
2005 22
2006 21
2007 17
2008 6
2009 14
2010 15
2011 16
2012 17
2013 19
2014 13
2015 10
2016 8
2017 10
2018 7
2019 8
2020 4
2021 4
2022 4
2023 1
2024 2
2025 4
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

507 results

Results by year

Filters applied: . Clear all
Page 1
Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine.
Maghbooli M, Golipour F, Moghimi Esfandabadi A, Yousefi M. Maghbooli M, et al. Phytother Res. 2014 Mar;28(3):412-5. doi: 10.1002/ptr.4996. Epub 2013 May 9. Phytother Res. 2014. PMID: 23657930 Clinical Trial.
Two hours after using either drug, mean headaches severity decreased significantly. Efficacy of ginger powder and sumatriptan was similar. Clinical adverse effects of ginger powder were less than sumatriptan. ...The effectiveness of ginger powder in the treatment of …
Two hours after using either drug, mean headaches severity decreased significantly. Efficacy of ginger powder and sumatriptan was sim …
Sumatriptan.
Kaube H, May A, Pfaffenrath V. Kaube H, et al. BMJ. 1994 Jun 11;308(6943):1573-4. doi: 10.1136/bmj.308.6943.1573d. BMJ. 1994. PMID: 8019338 Free PMC article. Clinical Trial. No abstract available.
Migraine.
Pilgrim AJ, Lloyd DK. Pilgrim AJ, et al. Lancet. 1992 Jul 4;340(8810):62. Lancet. 1992. PMID: 1351649 Clinical Trial. No abstract available.
Theory-based analysis of clinical efficacy of triptans using receptor occupancy.
Tokuoka K, Takayanagi R, Suzuki Y, Watanabe M, Kitagawa Y, Yamada Y. Tokuoka K, et al. J Headache Pain. 2014 Dec 8;15(1):85. doi: 10.1186/1129-2377-15-85. J Headache Pain. 2014. PMID: 25488888 Free PMC article. Clinical Trial.
Presently, 5 different triptans, namely sumatriptan, zolmitriptan, eletriptan, rizatriptan, and naratriptan, are marketed in Japan. ...
Presently, 5 different triptans, namely sumatriptan, zolmitriptan, eletriptan, rizatriptan, and naratriptan, are marketed in Japan. . …
Population Pharmacokinetics of Atogepant for the Prevention of Migraine.
Schlachter L, Stodtmann S, Voelkner A, Jonsson F, Lagraauw HM, Boinpally RR. Schlachter L, et al. Clin Pharmacokinet. 2026 Jan;65(1):149-164. doi: 10.1007/s40262-025-01566-5. Epub 2025 Nov 12. Clin Pharmacokinet. 2026. PMID: 41222899 Free PMC article. Clinical Trial.
Dose adjustments owing to intrinsic factors of age, sex, race, and body weight, or owing to concomitant medications consisting of P-glycoprotein (P-gp) inhibitors, BCRP inhibitors, oral contraceptive components (ethinyl estradiol and levonorgestrel), famotidine, esomeprazole, …
Dose adjustments owing to intrinsic factors of age, sex, race, and body weight, or owing to concomitant medications consisting of P-glycopro …
Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences.
Ferrari MD, James MH, Bates D, Pilgrim A, Ashford E, Anderson BA, Nappi G. Ferrari MD, et al. Cephalalgia. 1994 Oct;14(5):330-8. doi: 10.1046/j.1468-2982.1994.1405330.x. Cephalalgia. 1994. PMID: 7828190 Clinical Trial.
Oral sumatriptan in a dose of 100 mg aborts about 60% of migraine attacks within 2 h, but the headache may recur within 24 h. We investigated: (i) the incidence of headache recurrence after oral sumatriptan (ii) whether a second tablet of sumatriptan at 2 h i …
Oral sumatriptan in a dose of 100 mg aborts about 60% of migraine attacks within 2 h, but the headache may recur within 24 h. We inve …
The pharmacology of current anti-migraine drugs.
Peroutka SJ. Peroutka SJ. Headache. 1990 Jan;30(1 Suppl):5-11; discussion 24-8. doi: 10.1111/j.1526-4610.1990.hed30s1005.x. Headache. 1990. PMID: 1969855 Review.
The major finding of this analysis is that acute anti-migraine agents (e.g., ergots, sumatriptan) share high affinity for 5-HT1D receptors. This receptor appears to be present in certain intracranial blood vessels. ...
The major finding of this analysis is that acute anti-migraine agents (e.g., ergots, sumatriptan) share high affinity for 5-HT1D rece …
Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial.
Boinpally R, Jakate A, Butler M, Periclou A. Boinpally R, et al. Pain Manag. 2022 May;12(4):499-508. doi: 10.2217/pmt-2021-0073. Epub 2021 Dec 13. Pain Manag. 2022. PMID: 34898273 Free article. Clinical Trial.
Aim: To evaluate pharmacokinetic interactions of atogepant with sumatriptan, an open-label, randomized, crossover study was conducted. Patients & methods: Thirty healthy adults received atogepant 60 mg, sumatriptan 100 mg, or coadministered drugs. ...Results: At …
Aim: To evaluate pharmacokinetic interactions of atogepant with sumatriptan, an open-label, randomized, crossover study was conducted …
Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial.
Wienholtz NKF, Christensen CE, Zhang DG, Coskun H, Ghanizada H, Al-Karagholi MA, Hannibal J, Egeberg A, Thyssen JP, Ashina M. Wienholtz NKF, et al. Cephalalgia. 2021 May;41(6):731-748. doi: 10.1177/0333102420975395. Epub 2021 Feb 10. Cephalalgia. 2021. PMID: 33567890 Clinical Trial.
Of the 26 patients, four (15%) developed a PACAP38-induced migraine attack on sumatriptan and 11 patients (42%) on placebo (p = 0.016). There were no differences in area under the curve for headache intensity between sumatriptan (mean AUC 532) and placebo (mean AUC …
Of the 26 patients, four (15%) developed a PACAP38-induced migraine attack on sumatriptan and 11 patients (42%) on placebo (p = 0.016 …
A clinical trial of trimethobenzamide/diphenhydramine versus sumatriptan for acute migraines.
Friedman BW, Hochberg M, Esses D, Bijur PE, Corbo J, Paternoster J, Solorzano C, Toosi B, Lipton RB, Gallagher EJ. Friedman BW, et al. Headache. 2006 Jun;46(6):934-41. doi: 10.1111/j.1526-4610.2006.00467.x. Headache. 2006. PMID: 16732839 Clinical Trial.
No serious or frequent adverse effects were noted in either group. CONCLUSIONS: SQ sumatriptan is probably superior to TMB/DPH for treating the pain of acute migraine at 2 hours. However, TMB/DPH was well-tolerated, efficacious, and relieved pain comparably to sumatript …
No serious or frequent adverse effects were noted in either group. CONCLUSIONS: SQ sumatriptan is probably superior to TMB/DPH for tr …
507 results